Einträge von Dippel, Edgar auf dem Publikationsserver

Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian , Gutzmer, Ralf, Meier, Friedegund , Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian , Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas K., Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A., Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M., Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C. und Schadendorf, Dirk (2022) Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial. The Lancet 400 (10358), S. 1117-1129. Volltext nicht vorhanden.

Koch, Elias A. T., Petzold, Anne, Wessely, Anja , Dippel, Edgar, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica C. , Haferkamp, Sebastian, Kähler, Katharina C., Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike , Loquai, Carmen, Meier, Friedegund , Meissner, Markus , Mohr, Peter , Pföhler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk , Schell, Beatrice, Schlaak, Max , Terheyden, Patrick, Thoms, Kai-Martin, Schuler-Thurner, Beatrice, Ugurel, Selma , Ulrich, Jens, Utikal, Jochen , Weichenthal, Michael , Ziller, Fabian, Berking, Carola und Heppt, Markus V. (2022) Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. Cancers 14 (3), S. 518. Volltext nicht vorhanden.

Franklin, Cindy , Mohr, Peter, Bluhm, Leonie, Grimmelmann, Imke, Gutzmer, Ralf, Meier, Friedegund , Garzarolli, Marlene, Weichenthal, Michael , Pfoehler, Claudia, Herbst, Rudolf , Terheyden, Patrick, Utikal, Jochen, Ulrich, Jens, Debus, Dirk, Haferkamp, Sebastian, Kaatz, Martin, Forschner, Andrea, Leiter, Ulrike, Nashan, Dorothee, Kreuter, Alexander, Sachse, Michael, Welzel, Julia, Heinzerling, Lucie, Meiss, Frank, Weishaupt, Carsten, Gambichler, Thilo, Weyandt, Gerhard, Dippel, Edgar, Schatton, Kerstin, Celik, Eren, Trommer, Maike, Helfrich, Iris, Roesch, Alexander, Zimmer, Lisa , Livingstone, Elisabeth, Schadendorf, Dirk, Horn, Susanne und Ugurel, Selma (2022) Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Journal for ImmunoTherapy of Cancer 10 (6), e004509. Volltext nicht vorhanden.

Koch, Elias, Petzold, Anne, Wessely, Anja , Dippel, Edgar, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica, Haferkamp, Sebastian , Hohberger, Bettina, Kähler, Katharina, Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike, Loquai, Carmen, Meier, Friedegund, Meissner, Markus, Mohr, Peter, Pföhler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk, Schell, Beatrice, Schlaak, Max, Terheyden, Patrick, Thoms, Kai-Martin, Schuler-Thurner, Beatrice, Ugurel, Selma, Ulrich, Jens, Utikal, Jochen, Weichenthal, Michael, Ziller, Fabian, Berking, Carola und Heppt, Markus (2021) Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. Cancers 13 (13), S. 3359. Volltext nicht vorhanden.

Steeb, Theresa, Wessely, Anja, Alter, Mareike, Bayerl, Christiane, Bender, Armin, Bruning, Guido, Dabrowski, Evelyn, Debus, Dirk, Devereux, Nina, Dippel, Edgar, Drexler, Konstantin, Dücker, Pia, Dummer, Reinhard, Emmert, Steffen, Elsner, Peter, Enk, Alexander, Gebhardt, Christoffer, Gesierich, Anja, Goebeler, Matthias, Goerdt, Sergij, Goetze, Steven, Gutzmer, Ralf, Haferkamp, Sebastian, Hansel, Gesina, Hassel, Jessica C., Heinzerling, Lucie, Kähler, Katharina C., Kaume, Kjell M., Krapf, Wolfgang, Kreuzberg, Nicole, Lehmann, Percy, Livingstone, Elisabeth, Löffler, Harald, Loquai, Carmen, Mauch, Cornelia, Mangana, Johanna, Meier, Friedegund, Meissner, Markus, Moritz, Rose K. C., Maul, Lara Valeska, Müller, Verena, Mohr, Peter, Navarini, Alexander, Van Nguyen, Ahn, Pfeiffer, Christiane, Pföhler, Claudia, Posch, Christian, Richtig, Erika, Rompel, Rainer, Sachse, Michael M., Sauder, Stefanie, Schadendorf, Dirk, Schatton, Kerstin, Schulze, Hans-Joachim, Schultz, Erwin, Schilling, Bastian, Schmuth, Matthias, Simon, Jan. C., Streit, Markus, Terheyden, Patrick, Thiem, Alexander, Tüting, Thomas, Welzel, Julia, Weyandt, Gerhard, Wesselmann, Ulrich, Wollina, Uwe, Ziemer, Mirjana, Zimmer, Lisa, Zutt, Markus, Berking, Carola, Schlaak, Max und Heppt, Markus V. (2020) Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). Journal of Cancer Research and Clinical Oncology 147 (6), S. 1763-1771.

Zimmer, Lisa, Livingstone, Elisabeth, Hassel, Jessica C., Fluck, Michael, Eigentler, Thomas, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kieker, Felix, Dippel, Edgar, Rösch, Alexander, Simon, Jan-Christoph, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C., Schadendorf, Dirk, Berking, Carola, Herbst, Rudolf A., Martens, Uwe M., Sell, Sabine, Stadler, Rudolf, Terheyden, Patrick und Utikal, Jochen (2020) Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet 395 (10236), S. 1558-1568. Volltext nicht vorhanden.